CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 646 enrolled
Drug / intervention
placebo +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00790751
NCT00790751Phase 3Completed
CompareCT.gov

A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Avanafil (TA-1790) in Subjects With Generalized Erectile Dysfunction

VIVUS LLC·interventional·Posted Nov 13, 2008·Updated Jul 11, 2012

In Brief

A Phase 3 clinical trial evaluating placebo and avanafil for Erectile Dysfunction. Completed, enrolled 646 participants across 41 sites.

Detailed Summary

This study is being conducted to compare the safety and efficacy of 3 doses of avanafil to placebo in men with mild to severe erectile dysfunction.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsErectile Dysfunction
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 13, 2008
Enrollment StartNov 1, 2008
Primary CompletionAug 1, 2009
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 17.6 years ago

Interventions

placebodrug

30 minutes orally prior to initiation of sexual activity

avanafildrug

30 minutes orally prior to initiation of sexual activity

avanafildrug

30 minutes orally prior to initiation of sexual activity

avanafildrug

30 minutes orally prior to initiation of sexual activity